Treatment of Aspergillosis: Clinical Practice Guidelines of the Infectious Diseases Society of America

Voriconazole versus Amphotericin B for Primary Therapy of Invasive Aspergillosis

Herbrecht, R., Denning, D. W., Patterson, T. F., Bennett, J. E., Greene, R. E., Oestmann, J.-W., Kern, W. V., Marr, K. A., Ribaud, P., Lortholary, O., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa020191 · Cited by 3,304

Voriconazole Compared with Liposomal Amphotericin B for Empirical Antifungal Therapy in Patients with Neutropenia and Persistent Fever

Walsh, T. J., Pappas, P., Winston, D. J., Lazarus, H. M., Petersen, F., Raffalli, J., Yanovich, S., Stiff, P., Greenberg, R., Donowitz, G., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejm200201243460403 · Cited by 979

Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis

Denning, D. W., Ribaud, P., Milpied, N., Caillot, D., Herbrecht, R., Thiel, E., Haas, A., Ruhnke, M., & Lode, H. (2002) · Clinical Infectious Diseases · doi:10.1086/324620 · Cited by 844

Invasive Aspergillosis Disease Spectrum, Treatment Practices, and Outcomes

Patterson, T. F., Kirkpatrick, W. R., White, M., Hiemenz, J. W., WINGARD, J. R., DUPONT, B., RINALDI, M. G., STEVENS, D. A., & Graybill, J. R. (2000) · Medicine · doi:10.1097/00005792-200007000-00006 · Cited by 791

Allergic Bronchopulmonary Aspergillosis in Cystic Fibrosis—State of the Art: Cystic Fibrosis Foundation Consensus Conference

Stevens, D. A., Moss, R. B., Kurup, V. P., Knutsen, A. P., Greenberger, P., Judson, M. A., Denning, D. W., Crameri, R., Brody, A. S., Light, M., et al. (2003) · Clinical Infectious Diseases · doi:10.1086/376525 · Cited by 790

Multicenter Clinical Evaluation of the (1->3) -D-Glucan Assay as an Aid to Diagnosis of Fungal Infections in Humans

Ostrosky-Zeichner, L., Alexander, B. D., Kett, D. H., Vazquez, J., Pappas, P. G., Saeki, F., Ketchum, P. A., Wingard, J., Schiff, R., Tamura, H., et al. (2005) · Clinical Infectious Diseases · doi:10.1086/432470 · Cited by 669

Risks and outcomes of invasive fungal infections in recipients of allogeneic hematopoietic stem cell transplants after nonmyeloablative conditioning

Fukuda, T., Boeckh, M., Carter, R. A., Sandmaier, B. M., Maris, M. B., Maloney, D. G., Martin, P. J., Storb, R. F., & Marr, K. A. (2003) · Blood · doi:10.1182/blood-2003-02-0456 · Cited by 465

The Impact of Culture Isolation of Aspergillus Species: A Hospital‐Based Survey of Aspergillosis

Perfect, J. R., Cox, G. M., Lee, J. Y., Kauffman, C. A., de Repentigny, L., Chapman, S. W., Morrison, V. A., Pappas, P., Hiemenz, J. W., Stevens, D. A., et al. (2001) · Clinical Infectious Diseases · doi:10.1086/323900 · Cited by 458

Intravenous and Oral Itraconazole versus Intravenous Amphotericin B Deoxycholate as Empirical Antifungal Therapy for Persistent Fever in Neutropenic Patients with Cancer Who Are Receiving Broad-Spectrum Antibacterial Therapy: A Randomized, Controlled Trial

Boogaerts, M., Winston, D. J., Bow, E. J., Garber, G., Reboli, A. C., Schwarer, A. P., Novitzky, N., Boehme, A., Chwetzoff, E., De Beule, K., et al. (2001) · Annals of Internal Medicine · doi:10.7326/0003-4819-135-6-200109180-00010 · Cited by 321

Aspergillosis: Spectrum of Disease, Diagnosis, and Treatment

Barnes, P. D., & Marr, K. A. (2006) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2006.06.001 · Cited by 205

Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021

Evans, L., Rhodes, A., Alhazzani, W., Antonelli, M., Coopersmith, C. M., French, C., Machado, F. R., Mcintyre, L., Ostermann, M., Prescott, H. C., et al. (2021) · Intensive Care Medicine · doi:10.1007/s00134-021-06506-y · Cited by 5,082

Revised Definitions of Invasive Fungal Disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group

De Pauw, B., Walsh, T. J., Donnelly, J. P., Stevens, D. A., Edwards, J. E., Calandra, T., Pappas, P. G., Maertens, J., Lortholary, O., Kauffman, C. A., et al. (2008) · Clinical Infectious Diseases · doi:10.1086/588660 · Cited by 4,917

Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America

Patterson, T. F., Thompson, G. R., Denning, D. W., Fishman, J. A., Hadley, S., Herbrecht, R., Kontoyiannis, D. P., Marr, K. A., Morrison, V. A., Nguyen, M. H., et al. (2016) · Clinical Infectious Diseases · doi:10.1093/cid/ciw326 · Cited by 2,926

Chronic pulmonary aspergillosis: rationale and clinical guidelines for diagnosis and management

Denning, D. W., Cadranel, J., Beigelman-Aubry, C., Ader, F., Chakrabarti, A., Blot, S., Ullmann, A. J., Dimopoulos, G., & Lange, C. (2016) · European Respiratory Journal · doi:10.1183/13993003.00583-2015 · Cited by 1,030

Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial

Maertens, J. A., Raad, I. I., Marr, K. A., Patterson, T. F., Kontoyiannis, D. P., Cornely, O. A., Bow, E. J., Rahav, G., Neofytos, D., Aoun, M., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01159-9 · Cited by 1,001

Antifungal drug resistance: mechanisms, epidemiology, and consequences for treatment

Pfaller, M. A. (2012) · The American Journal of Medicine · doi:10.1016/j.amjmed.2011.11.001 · Cited by 903

Epidemiology of Invasive Mycoses in North America

Pfaller, M. A., & Diekema, D. J. (2010) · Critical Reviews in Microbiology · doi:10.3109/10408410903241444 · Cited by 901

The clinical spectrum of pulmonary aspergillosis

Kosmidis, C., & Denning, D. W. (2015) · Thorax · doi:10.1136/thoraxjnl-2014-206291 · Cited by 850

Frequency and Evolution of Azole Resistance in Aspergillus fumigatus Associated with Treatment Failure1

Howard, S. J., Cerar, D., Anderson, M. J., Albarrag, A., Fisher, M. C., Pasqualotto, A. C., Laverdiere, M., Arendrup, M. C., Perlin, D. S., & Denning, D. W. (2009) · Emerging Infectious Diseases · doi:10.3201/eid1507.090043 · Cited by 750

The biology and chemistry of antifungal agents: A review

Kathiravan, M. K., Salake, A. B., Chothe, A. S., Dudhe, P. B., Watode, R. P., Mukta, M. S., & Gadhwe, S. (2012) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2012.04.045 · Cited by 664

Azole resistance in Aspergillus fumigatus: a side-effect of environmental fungicide use?

Verweij, P. E., Snelders, E., Kema, G. H., Mellado, E., & Melchers, W. J. (2009) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(09)70265-8 · Cited by 604

Guidelines for the diagnosis and antibiotic treatment of endocarditis in adults: a report of the Working Party of the British Society for Antimicrobial Chemotherapy

Gould, F. K., Denning, D. W., Elliott, T. S. J., Foweraker, J., Perry, J. D., Prendergast, B. D., Sandoe, J. A. T., Spry, M. J., & Watkin, R. W. (2012) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkr450 · Cited by 593

A Guide to Utilization of the Microbiology Laboratory for Diagnosis of Infectious Diseases: 2013 Recommendations by the Infectious Diseases Society of America (IDSA) and the American Society for Microbiology (ASM)a

Baron, E. J., Miller, J. M., Weinstein, M. P., Richter, S. S., Gilligan, P. H., Thomson, R. B., Bourbeau, P., Carroll, K. C., Kehl, S. C., Dunne, W. M., et al. (2013) · Clinical Infectious Diseases · doi:10.1093/cid/cit278 · Cited by 592

Azole Resistance in Aspergillus fumigatus : Can We Retain the Clinical Use of Mold-Active Antifungal Azoles?

Verweij, P. E., Chowdhary, A., Melchers, W. J. G., & Meis, J. F. (2016) · Clinical Infectious Diseases · doi:10.1093/cid/civ885 · Cited by 561

Liposomal Amphotericin B (AmBisome®): A Review of the Pharmacokinetics, Pharmacodynamics, Clinical Experience and Future Directions

Stone, N. R. H., Bicanic, T., Salim, R., & Hope, W. (2016) · Drugs · doi:10.1007/s40265-016-0538-7 · Cited by 537

Combination Antifungal Therapy for Invasive Aspergillosis: A Randomized Trial

Marr, K. A., Schlamm, H. T., Herbrecht, R., Rottinghaus, S. T., Bow, E. J., Cornely, O. A., Heinz, W. J., Jagannatha, S., Koh, L. P., Kontoyiannis, D. P., et al. (2015) · Annals of Internal Medicine · doi:10.7326/m13-2508 · Cited by 514

Molecular Evolution of Antifungal Drug Resistance

Robbins, N., Caplan, T., & Cowen, L. E. (2017) · Annual Review of Microbiology · doi:10.1146/annurev-micro-030117-020345 · Cited by 441

Antifungal Therapy: New Advances in the Understanding and Treatment of Mycosis

Scorzoni, L., de Paula e Silva, A. C. A., Marcos, C. M., Assato, P. A., de Melo, W. C. M. A., de Oliveira, H. C., Costa-Orlandi, C. B., Mendes-Giannini, M. J. S., & Fusco-Almeida, A. M. (2017) · Frontiers in Microbiology · doi:10.3389/fmicb.2017.00036 · Cited by 418

Echinocandin Antifungal Drugs in Fungal Infections: A Comparison

Chen, S. C.-A., Slavin, M. A., & Sorrell, T. C. (2011) · Drugs · doi:10.2165/11585270-000000000-00000 · Cited by 371

Use of PCR for diagnosis of invasive aspergillosis: systematic review and meta-analysis

Mengoli, C., Cruciani, M., Barnes, R. A., Loeffler, J., & Donnelly, J. P. (2009) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(09)70019-2 · Cited by 354

Antifungal Agents

Nett, J. E., & Andes, D. R. (2016) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2015.10.012 · Cited by 351

Aspergillosis due to Voriconazole Highly Resistant Aspergillus fumigatus and Recovery of Genetically Related Resistant Isolates From Domiciles

van der Linden, J. W. M., Camps, S. M. T., Kampinga, G. A., Arends, J. P. A., Debets-Ossenkopp, Y. J., Haas, P. J. A., Rijnders, B. J. A., Kuijper, E. J., van Tiel, F. H., Varga, J., et al. (2013) · Clinical Infectious Diseases · doi:10.1093/cid/cit320 · Cited by 342

Nosocomial Fungal Infections: Epidemiology, Infection Control, and Prevention

Alangaden, G. J. (2011) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2010.11.003 · Cited by 337

Epidemiological trends in invasive aspergillosis in France: the SAIF network (2005–2007)

Lortholary, O., Gangneux, J.-P., Sitbon, K., Lebeau, B., de Monbrison, F., Le Strat, Y., Coignard, B., Dromer, F., & Bretagne, S. (2011) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2011.03548.x · Cited by 331

High-frequency Triazole Resistance Found In Nonculturable Aspergillus fumigatus from Lungs of Patients with Chronic Fungal Disease

Denning, D. W., Park, S., Lass-Florl, C., Fraczek, M. G., Kirwan, M., Gore, R., Smith, J., Bueid, A., Moore, C. B., Bowyer, P., et al. (2011) · Clinical Infectious Diseases · doi:10.1093/cid/cir179 · Cited by 313

Therapy for fungal diseases: opportunities and priorities

Denning, D. W., & Hope, W. W. (2010) · Trends in Microbiology · doi:10.1016/j.tim.2010.02.004 · Cited by 314

Factors associated with mortality in transplant patients with invasive aspergillosis

Baddley, J. W., Andes, D. R., Marr, K. A., Kontoyiannis, D. P., Alexander, B. D., Kauffman, C. A., Oster, R. A., Anaissie, E. J., Walsh, T. J., Schuster, M. G., et al. (2010) · Clinical Infectious Diseases · doi:10.1086/652768 · Cited by 303

Epidemiology of opportunistic fungal infections in Latin America

Nucci, M., Queiroz‐Telles, F., Tobón, A. M., Restrepo, A., & Colombo, A. L. (2010) · Clinical Infectious Diseases · doi:10.1086/655683 · Cited by 280

Azole antifungals: 35 years of invasive fungal infection management

Allen, D., Wilson, D., Drew, R., & Perfect, J. (2015) · Expert Review of Anti-infective Therapy · doi:10.1586/14787210.2015.1032939 · Cited by 255

The PATH (Prospective Antifungal Therapy) Alliance® registry and invasive fungal infections: update 2012

Azie, N., Neofytos, D., Pfaller, M., Meier-Kriesche, H.-U., Quan, S.-P., & Horn, D. (2012) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2012.06.012 · Cited by 222

Echinocandins: The newest class of antifungals

Sucher, A. J., Chahine, E. B., & Balcer, H. E. (2009) · Annals of Pharmacotherapy · doi:10.1345/aph.1m237 · Cited by 213

Detection of galactomannan in bronchoalveolar lavage fluid samples of patients at risk for invasive pulmonary aspergillosis: analytical and clinical validity

D'Haese, J., Theunissen, K., Vermeulen, E., Schoemans, H., De Vlieger, G., Lammertijn, L., Meersseman, P., Meersseman, W., Lagrou, K., & Maertens, J. (2012) · Journal of Clinical Microbiology · doi:10.1128/jcm.06423-11 · Cited by 186

Wild-type MIC distributions and epidemiological cutoff values for amphotericin B, flucytosine, and itraconazole and Candida spp. as determined by CLSI broth microdilution.

Pfaller, M. A., Espinel-Ingroff, A., Canton, E., Castanheira, M., Cuenca-Estrella, M., Diekema, D. J., Fothergill, A., Fuller, J., Ghannoum, M., Jones, R. N., et al. (2012) · Journal of Clinical Microbiology · doi:10.1128/jcm.00248-12 · Cited by 174

Adverse interactions between antifungal azoles and vincristine: review and analysis of cases

Moriyama, B., Henning, S. A., Leung, J., Falade‐Nwulia, O., Jarosinski, P., Penzak, S. R., & Walsh, T. J. (2012) · Mycoses · doi:10.1111/j.1439-0507.2011.02158.x · Cited by 164

Efficacy of oral E1210, a new broad-spectrum antifungal with a novel mechanism of action, in murine models of candidiasis, aspergillosis, and fusariosis

Hata, K., Horii, T., Miyazaki, M., Watanabe, N.-A., Okubo, M., Sonoda, J., Nakamoto, K., Tanaka, K., Shirotori, S., Murai, N., et al. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00366-11 · Cited by 149

Incidence of systemic fungal infection and related mortality following severe burns

Murray, C. K., Loo, F. L., Hospenthal, D. R., Cancio, L. C., Jones, J. A., Kim, S. H., Holcomb, J. B., Wade, C. E., & Wolf, S. E. (2008) · Burns · doi:10.1016/j.burns.2008.04.007 · Cited by 149

Echinocandins in antifungal pharmacotherapy

Patil, A., & Majumdar, S. (2017) · Journal of Pharmacy and Pharmacology · doi:10.1111/jphp.12780 · Cited by 145

Targeting the Fungal Cell Wall: Current Therapies and Implications for Development of Alternative Antifungal Agents

Hasim, S., & Coleman, J. J. (2019) · Future Medicinal Chemistry · doi:10.4155/fmc-2018-0465 · Cited by 144

Triazole Resistance in Aspergillus spp.: A Worldwide Problem?

Rivero-Menendez, O., Alastruey-Izquierdo, A., Mellado, E., & Cuenca-Estrella, M. (2016) · Journal of Fungi · doi:10.3390/jof2030021 · Cited by 142

Activity of MGCD290, a Hos2 Histone Deacetylase Inhibitor, in Combination with Azole Antifungals against Opportunistic Fungal Pathogens

Pfaller, M. A., Messer, S. A., Georgopapadakou, N., Martell, L. A., Besterman, J. M., & Diekema, D. J. (2009) · Journal of Clinical Microbiology · doi:10.1128/jcm.00618-09 · Cited by 143

In-host adaptation and acquired triazole resistance in Aspergillus fumigatus: a dilemma for clinical management

Verweij, P. E., Zhang, J., Debets, A. J. M., Meis, J. F., van de Veerdonk, F. L., Schoustra, S. E., Zwaan, B. J., & Melchers, W. J. G. (2016) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(16)30138-4 · Cited by 140

Voriconazole for secondary prophylaxis of invasive fungal infections in allogeneic stem cell transplant recipients: results of the VOSIFI study

Cordonnier, C., Rovira, M., Maertens, J., Olavarria, E., Faucher, C., Bilger, K., Pigneux, A., Cornely, O. A., Ullmann, A. J., Bofarull, R. M., et al. (2010) · Haematologica · doi:10.3324/haematol.2009.020073 · Cited by 137

Breakpoints for antifungal agents: An update from EUCAST focussing on echinocandins against Candida spp. and triazoles against Aspergillus spp.

Arendrup, M. C., Cuenca-Estrella, M., Lass-Flörl, C., & Hope, W. W. (2013) · Drug Resistance Updates · doi:10.1016/j.drup.2014.01.001 · Cited by 129

Central Role of the Trehalose Biosynthesis Pathway in the Pathogenesis of Human Fungal Infections: Opportunities and Challenges for Therapeutic Development

Thammahong, A., Puttikamonkul, S., Perfect, J. R., Brennan, R. G., & Cramer, R. A. (2017) · Microbiology and Molecular Biology Reviews · doi:10.1128/mmbr.00053-16 · Cited by 125

Mevalonate governs interdependency of ergosterol and siderophore biosyntheses in the fungal pathogen Aspergillus fumigatus

Yasmin, S., Alcazar-Fuoli, L., Gründlinger, M., Puempel, T., Cairns, T., Blatzer, M., Lopez, J. F., Grimalt, J. O., Bignell, E., & Haas, H. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1106399108 · Cited by 126

Molecular Tools for the Detection and Deduction of Azole Antifungal Drug Resistance Phenotypes in Aspergillus Species

Dudakova, A., Spiess, B., Tangwattanachuleeporn, M., Sasse, C., Buchheidt, D., Weig, M., Groß, U., & Bader, O. (2017) · Clinical Microbiology Reviews · doi:10.1128/cmr.00095-16 · Cited by 113

Echinocandins: the expanding antifungal armamentarium

Aguilar-Zapata, D., Petraitiene, R., & Petraitis, V. (2015) · Clinical Infectious Diseases · doi:10.1093/cid/civ814 · Cited by 112

Echinocandin Resistance, Susceptibility Testing and Prophylaxis: Implications for Patient Management

Perlin, D. S. (2014) · Drugs · doi:10.1007/s40265-014-0286-5 · Cited by 99

Management of invasive fungal infections: a role for polyenes

Chandrasekar, P. (2011) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkq479 · Cited by 100

In Vitro Activity of a New Oral Glucan Synthase Inhibitor (MK-3118) Tested against Aspergillus spp. by CLSI and EUCAST Broth Microdilution Methods

Pfaller, M. A., Messer, S. A., Motyl, M. R., Jones, R. N., & Castanheira, M. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01588-12 · Cited by 98

Use of Epidemiological Cutoff Values To Examine 9-Year Trends in Susceptibility of Aspergillus Species to the Triazoles

Pfaller, M., Boyken, L., Hollis, R., Kroeger, J., Messer, S., Tendolkar, S., & Diekema, D. (2011) · Journal of Clinical Microbiology · doi:10.1128/jcm.02136-10 · Cited by 91

In Vitro and In Vivo Antifungal Profile of a Novel and Long-Acting Inhaled Azole, PC945, on Aspergillus fumigatus Infection

Colley, T., Alanio, A., Kelly, S. L., Sehra, G., Kizawa, Y., Warrilow, A. G. S., Parker, J. E., Kelly, D. E., Kimura, G., Anderson-Dring, L., et al. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02280-16 · Cited by 87

In Vitro Activity of Calcineurin and Heat Shock Protein 90 Inhibitors against Aspergillus fumigatus Azole- and Echinocandin-Resistant Strains

Lamoth, F., Juvvadi, P. R., Gehrke, C., & Steinbach, W. J. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01857-12 · Cited by 88

Mitochondrial dynamics in the pathogenic mold Aspergillus fumigatus : therapeutic and evolutionary implications

Neubauer, M., Zhu, Z., Penka, M., Helmschrott, C., Wagener, N., & Wagener, J. (2015) · Molecular Microbiology · doi:10.1111/mmi.13167 · Cited by 76

Chronic Pulmonary Aspergillosis—Where Are We? and Where Are We Going?

Hayes, G., & Novak-Frazer, L. (2016) · Journal of Fungi · doi:10.3390/jof2020018 · Cited by 77

The Aspergillus fumigatus CrzA Transcription Factor Activates Chitin Synthase Gene Expression during the Caspofungin Paradoxical Effect

Ries, L. N. A., Rocha, M. C., de Castro, P. A., Silva-Rocha, R., Silva, R. N., Freitas, F. Z., de Assis, L. J., Bertolini, M. C., Malavazi, I., & Goldman, G. H. (2017) · mBio · doi:10.1128/mbio.00705-17 · Cited by 76

Diagnostic accuracy of a novel lateral-flow device in invasive aspergillosis: a meta-analysis

Pan, Z., Fu, M., Zhang, J., Zhou, H., Fu, Y., & Zhou, J. (2015) · Journal of Medical Microbiology · doi:10.1099/jmm.0.000092 · Cited by 76

Identification of a Key Lysine Residue in Heat Shock Protein 90 Required for Azole and Echinocandin Resistance in Aspergillus fumigatus

Lamoth, F., Juvvadi, P. R., Soderblom, E. J., Moseley, M. A., Asfaw, Y. G., & Steinbach, W. J. (2014) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02286-13 · Cited by 74

Invasive fungal infections in acute leukemia

Bhatt, V. R., Viola, G. M., & Ferrajoli, A. (2011) · Therapeutic Advances in Hematology · doi:10.1177/2040620711410098 · Cited by 71

Triazole fungicides and the selection of resistance to medical triazoles in the opportunistic mould Aspergillus fumigatus

Verweij, P. E., Kema, G. H., Zwaan, B., & Melchers, W. J. (2013) · Pest Management Science · doi:10.1002/ps.3390 · Cited by 67

Hospital costs and outcomes among intravenous antifungal therapies for patients with invasive aspergillosis in the United States

Kim, A., Nicolau, D. P., & Kuti, J. L. (2011) · Mycoses · doi:10.1111/j.1439-0507.2010.01903.x · Cited by 60

Diagnosis of invasive aspergillosis: recent developments and ongoing challenges

Arvanitis, M., & Mylonakis, E. (2015) · European Journal of Clinical Investigation · doi:10.1111/eci.12448 · Cited by 56

Trends in antifungal use in US hospitals, 2006–12

Vallabhaneni, S., Baggs, J., Tsay, S., Srinivasan, A. R., Jernigan, J. A., & Jackson, B. R. (2018) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dky270 · Cited by 45

Gene co-expression analysis identifies gene clusters associated with isotropic and polarized growth in Aspergillus fumigatus conidia

Baltussen, T. J. H., Coolen, J. P. M., Zoll, J., Verweij, P. E., & Melchers, W. J. G. (2018) · Fungal Genetics and Biology · doi:10.1016/j.fgb.2018.04.013 · Cited by 43

Fungal infections in the ICU

Zilberberg, M. D., & Shorr, A. F. (2009) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2009.04.008 · Cited by 42

In Vitro Interaction of Voriconazole and Anidulafungin against Triazole-Resistant Aspergillus fumigatus

Seyedmousavi, S., Meletiadis, J., Melchers, W. J. G., Rijs, A. J. M. M., Mouton, J. W., & Verweij, P. E. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00980-12 · Cited by 38

Fungal Infections in Transplant and Oncology Patients

Person, A. K., Kontoyiannis, D. P., & Alexander, B. D. (2011) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2010.11.013 · Cited by 33

Echinocandins: Addressing outstanding questions surrounding treatment of invasive fungal infections

Holt, S. L., & Drew, R. H. (2011) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp100456 · Cited by 26

Comparative in vivo dose-dependent activity of caspofungin and anidulafungin against echinocandin-susceptible and -resistant Aspergillus fumigatus

Lewis, R. E., Liao, G., Hou, J., Prince, R. A., & Kontoyiannis, D. P. (2011) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkr142 · Cited by 23

Evaluation of the safety and efficacy of micafungin in Japanese patients with deep mycosis: a post-marketing survey report

Hanadate, T., Wakasugi, M., Sogabe, K., Kobayashi, T., Horita, H., Kawamura, I., Matsui, K., Sou, M., Hori, Y., & Hoshino, Y. (2011) · Journal of Infection and Chemotherapy · doi:10.1007/s10156-011-0219-0 · Cited by 21

Invasive Aspergillosis in Hematological Patients

Kimura, S.-I. (2016) · Medical Mycology Journal · doi:10.3314/mmj.57.j77 · Cited by 14

Special considerations for the diagnosis and treatment of invasive pulmonary aspergillosis

McCarthy, M. W., & Walsh, T. J. (2017) · Expert Review of Respiratory Medicine · doi:10.1080/17476348.2017.1340835 · Cited by 8

Prevalence of and environmental factors associated with aerosolised Aspergillus spores at a zoological park

Martony, M., Nollens, H., Tucker, M., Henry, L., Schmitt, T., & Hernandez, J. (2019) · Veterinary Record Open · doi:10.1136/vetreco-2018-000281 · Cited by 5

Genetic variations of CYP3A4 on the metabolism of itraconazole in vitro

Xie, S.-L., Zhu, X., Gao, N., Lin, Q., Chen, C., Yang, Y.-J., Cai, J.-P., Hu, G.-X., & Xu, R.-A. (2023) · Food and Chemical Toxicology · doi:10.1016/j.fct.2023.114101 · Cited by 5